Literature DB >> 1389454

The association of thyroid dyshormonogenesis and deafness (Pendred syndrome): experience of the Victorian Neonatal Thyroid Screening Programme.

J C Coakley1, E H Keir, J F Connelly.   

Abstract

Between 1977 and 1989, the Victorian Neonatal Thyroid Screening Programme detected five subjects with thyroid dyshormonogenesis and sensorineural deafness. These patients have been diagnosed as having Pendred syndrome. In two of the children, thyroid function tests which were initially abnormal at birth returned to normal spontaneously without treatment. However, hypothyroidism subsequently recurred and the children required thyroxine therapy. These two children could have been mistakenly diagnosed as having transient hypothyroidism. The detection of five patients with Pendred syndrome illustrates the importance of audiological assessment in all babies with thyroid dyshormonogenesis in whom there is increased uptake of isotope on thyroid scanning. In our experience, hearing loss in patients with Pendred syndrome may be progressive over time, so that repeated audiological assessments are necessary.

Entities:  

Mesh:

Year:  1992        PMID: 1389454     DOI: 10.1111/j.1440-1754.1992.tb02700.x

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  3 in total

Review 1.  Pendred syndrome.

Authors:  W Reardon; R C Trembath
Journal:  J Med Genet       Date:  1996-12       Impact factor: 6.318

2.  Prevalence, age of onset, and natural history of thyroid disease in Pendred syndrome.

Authors:  W Reardon; R Coffey; T Chowdhury; A Grossman; H Jan; K Britton; P Kendall-Taylor; R Trembath
Journal:  J Med Genet       Date:  1999-08       Impact factor: 6.318

3.  Pendred syndrome among patients with congenital hypothyroidism detected by neonatal screening: identification of two novel PDS/SLC26A4 mutations.

Authors:  Karolina Banghova; Eva Al Taji; Ondrej Cinek; Dana Novotna; Radka Pourova; Jirina Zapletalova; Olga Hnikova; Jan Lebl
Journal:  Eur J Pediatr       Date:  2007-09-18       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.